<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00333099</url>
  </required_header>
  <id_info>
    <org_study_id>CHU63-0012</org_study_id>
    <nct_id>NCT00333099</nct_id>
  </id_info>
  <brief_title>INEC Study: Immuno-modulating Enteral Nutrition in Cancer</brief_title>
  <official_title>Effect of Enteral Immunonutrition During Chemoradiotherapy in Patients With Head and Neck Cancer or Esophageal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Clermont-Ferrand</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fonds National d'Aménagement et de Développement du territoire (FNADT)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fonds Européens de développement Régional (FEDER)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Jean Perrin</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Leon Berard</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Institut de Cancérologie de la Loire</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hôpital Edouard Herriot</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Grenoble</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Orkyn'</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University Hospital, Clermont-Ferrand</source>
  <brief_summary>
    <textblock>
      The aim of this study is to investigate if enteral immunonutrition of head and neck or
      esophageal cancer patients, using an arginine, omega 3 fatty acid, nucleotides-enhanced diet
      [Impact (R), Novartis] versus a standard enteral nutrition (control, Novartis), could improve
      clinical outcomes (mucositis frequency, treatment tolerance), nutritional and immune status,
      and life quality parameters.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Malnutrition is frequent in head and neck (H&amp;N) and esophageal cancers and alters immune
      status, anti-infectious and anti-tumoral defenses and the response to the treatment (surgery,
      chemotherapy, radiotherapy). Treatment of these 2 types of cancer is often chemoradiotherapy
      which frequently induces mucositis. Mucositis enhances nutritional risk and could impose a
      modification or an interruption of the treatment. The aim of this study is to investigate if
      enteral immunonutrition of head and neck or esophageal cancer patients, using an arginine,
      omega 3 fatty acid, nucleotides-enhanced diet [Impact(R), Novartis] versus a standard enteral
      nutrition (control, Novartis), could improve clinical outcomes (mucositis frequency,
      treatment tolerance), nutritional and immune status, and life quality parameters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2006</start_date>
  <completion_date type="Actual">September 2011</completion_date>
  <primary_completion_date type="Actual">September 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Frequency and grade of mucositis</measure>
    <time_frame>each visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect on treatment conditions (interruption, doses)</measure>
    <time_frame>each visit</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other complications linked to chemoradiotherapy</measure>
    <time_frame>each week of chemoradiotherapy</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional and immune status</measure>
    <time_frame>at randomisation's visit, visit at the end of treatment, 1, 6 and 12 months after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Life quality</measure>
    <time_frame>at randomisation's visit, visit at the end of treatment, 6 and 12 months after the end of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost</measure>
    <time_frame>each visit</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Malnutrition</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Head and Neck Cancer</condition>
  <arm_group>
    <arm_group_label>nutrition</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>study of immuno-modulating enteral nutrition</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Impact (R) Enteral Nutrition</intervention_name>
    <description>mucositis frequency, treatment tolerance</description>
    <arm_group_label>nutrition</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>impact</intervention_name>
    <description>1500 calories every day :
-5 days before the begining of the chemoradiotherapy and until the last day of the treatment</description>
    <arm_group_label>nutrition</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  H&amp;N and esophageal cancer patients, not treated by surgery and needing
             chemoradiotherapy

          -  Performance status: Objective Mucositis Score (OMS) of 0, 1, 2 or Karnofsky &gt; 50%

          -  Acceptance of a gastrostomy, jejunostomy or a nasogastric tube to conduct enteral
             nutrition

          -  Informed consent form signed

        Exclusion Criteria:

          -  H&amp;N cancer treated by exclusive radiotherapy

          -  H&amp;N and esophageal cancer which can be treated by exclusive surgery

          -  Tonsil cancer

          -  Existence of metastases

          -  Concomitant cancer

          -  Repeat of cancer at site

          -  Insulin dependant diabetes

          -  Thyroid diseases

          -  Subjects with major surgery or severe infectious status in the 3 preceding months

          -  Biological assessment incompatible with the esophagus chemotherapy treatment
             (polynuclear cells &lt; 1500/ml; blood platelets &lt; 100000/ml; serum creatinine &gt; 130
             µmol/ml; ASAT, ALAT, ALP and bilirubin &gt; twice the norm)

          -  Patients taking food or supplements enriched with omega 3 (arginine and nucleotides),
             during the period of the study and in the preceding month

          -  Breast feeding women or in period of fertility without effective means of
             contraception

          -  Patients who refuse to participate or are unable to receive information or are unable
             to sign written informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Corinne Bouteloup, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hotel Dieu Service d'Hepato-Gastro-Enterologie (service du Pr G. Bommelaer) Clermont-Ferrand</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marie-Paule Vasson, Professor</last_name>
    <role>Study Director</role>
    <affiliation>CLAN, Unité de Nutrition, Centre Jean Perrin (Clermont-Ferrand)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hotel Dieu</name>
      <address>
        <city>Clermont-Ferrand</city>
        <state>Auvergne</state>
        <zip>63058</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.canceropole-clara.com</url>
  </link>
  <reference>
    <citation>van Bokhorst-de van der Schuer, van Leeuwen PA, Kuik DJ, Klop WM, Sauerwein HP, Snow GB, Quak JJ. The impact of nutritional status on the prognoses of patients with advanced head and neck cancer. Cancer. 1999 Aug 1;86(3):519-27.</citation>
    <PMID>10430262</PMID>
  </reference>
  <reference>
    <citation>Nozoe T, Kimura Y, Ishida M, Saeki H, Korenaga D, Sugimachi K. Correlation of pre-operative nutritional condition with post-operative complications in surgical treatment for oesophageal carcinoma. Eur J Surg Oncol. 2002 Jun;28(4):396-400.</citation>
    <PMID>12099649</PMID>
  </reference>
  <reference>
    <citation>Gianotti L, Braga M, Nespoli L, Radaelli G, Beneduce A, Di Carlo V. A randomized controlled trial of preoperative oral supplementation with a specialized diet in patients with gastrointestinal cancer. Gastroenterology. 2002 Jun;122(7):1763-70.</citation>
    <PMID>12055582</PMID>
  </reference>
  <reference>
    <citation>de Luis DA, Arranz M, Aller R, Izaola O, Cuellar L, Terroba MC. Immunoenhanced enteral nutrition, effect on inflammatory markers in head and neck cancer patients. Eur J Clin Nutr. 2005 Jan;59(1):145-7.</citation>
    <PMID>15266308</PMID>
  </reference>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 1, 2006</study_first_submitted>
  <study_first_submitted_qc>June 1, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 2, 2006</study_first_posted>
  <last_update_submitted>September 13, 2012</last_update_submitted>
  <last_update_submitted_qc>September 13, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 14, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Enteral nutrition</keyword>
  <keyword>immunonutrients</keyword>
  <keyword>head and neck cancer</keyword>
  <keyword>esophageal cancer</keyword>
  <keyword>chemoradiotherapy</keyword>
  <keyword>H&amp;N or esophageal cancer patients with a chemoradiotherapy treatment.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Malnutrition</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

